Bay 55-9837

Cat. No. 2711 5 篇引用文献提交评论说明书 / 分析证书（CoA） / 化学品安全技术说明书（SDS）

Pricing	Availability		Qty

说明： Potent and selective VPAC₂ agonist

纯度： ≥95% (HPLC)

引用文献 (5)

生物活性技术数据溶解性计算器说明书参考文献

生物活性 for Bay 55-9837

Bay 55-9837 is a selective VPAC₂ receptor agonist (EC₅₀ values are 0.4, 100 and >1000 nM for VPAC₂, VPAC₁ and PAC₁, respectively in a cAMP accumulation assay; IC₅₀ values are 60, 8700 and >10000 nM for VPAC₂, VPAC₁ and PAC₁, respectively in a competition binding assay). Stimulates glucose-dependent insulin secretion in isolated human pancreatic islets. Reduces HIV-1 viral replication and shows cooperative effects when given in conjunction with VPAC₁ agonists.

技术数据 for Bay 55-9837

分子量	3742.29
公式	C₁₆₇H₂₇₀N₅₂O₄₆
序列	HSDAVFTDNYTRLRKQVAAKKYLQSIKNKRY (Modifications: Tyr-31 = C-terminal amide)
储存	Store at -20°C
纯度	≥95% (HPLC)
CAS Number	463930-25-8
PubChem ID	72941824
InChI Key	NHMJBXFCQMBYCP-ZBLLYJRDSA-N
Smiles	[H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(N)=O

上方提供的技术数据仅供参考。批次相关数据请参见分析证书。

Tocris products are intended for laboratory research use only, unless stated otherwise.

溶解性数据 for Bay 55-9837

溶解性	Soluble to 2 mg/ml in water

产品说明书 for Bay 55-9837

分析证书/产品说明书

化学品安全技术说明书

参考文献 for Bay 55-9837

参考文献是支持产品生物活性的出版物。

Tsutsumi et al (2002) A potent and highly selective VPAC2 agonist enhances glucose-induced Ins release and glucose disposal: a potential therapy for type 2 diabetes. Diabetes 51 1453 PMID: 11978642

Clairmont et al (2006) Engineering of a VPAC2 receptor peptide agonist to impart dipeptidyl peptidase IV stability and enhance in vivo glucose disposal. J.Med.Chem. 49 7545 PMID: 17149884

Pan et al (2007) Engineering novel VPAC2-selective agonists with improved stability and glucose-lowering activity in vivo. J.Pharmacol.Exp.Ther. 320 900 PMID: 17110523

Temerozo et al (2013) Macrophage resistance to HIV-1 infection is enhanced by the neuropeptides VIP and PACAP. PLoS ONE 8 67701 PMID: 23818986

If you know of a relevant reference for Bay 55-9837, please let us know.

按标靶查看相关产品

按产品操作查看相关产品

查看全部 VIP Receptor Agonists

关键词: BAY 55-9837, BAY 55-9837 supplier, Potent, selective, VPAC2, agonists, Vasoactive, Intestinal, Peptide, Receptors, VPAC, VIP, BAY55-9837, HIV, 2711, Tocris Bioscience